ArticleCase reports in oncology
A Rare Presentation of Multiple Myeloma as a Second Primary Cancer Sequential to Non-Hodgkin Lymphoma: Case Report.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetic and clinical insights into the coexistence of multiple myeloma and diffuse large B cell lymphoma from a case report and systematic review with bioinformatics analysis.Discover oncology · 2026Article
- Karyotype evolution of multiple myeloma.Journal of clinical and experimental hematopathology : JCEH · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The sequential occurrence of diffuse large B-cell lymphoma (DLBCL) a common type of non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) is exceedingly rare, presenting a significant challenge in both diagnosis and treatment. Case Presentation: The case report discusses a 60-year-old male patient with a history of DLBCL which was diagnosed following symptoms of fever, weight loss and night sweats. He was treated with RVP (rituximab 375 mg/m Conclusion: This report highlights the case of a treated DLBCL which subsequently led to the rare development of new onset MM following a prolonged remission. It underscores the importance of long-term surveillance and effective management toward addressing the sequential hematological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.